NuVasive has added the AttraX putty to its US biologics range.
AttraX Putty is a next-generation, synthetic bone graft product indicated for use as an autograft extender in posterolateral spine surgery. The biotextured surface features of AttraX putty is designed to help drive regeneration of bone at the implanted site.
“We are excited to officially launch AttraX Putty for surgical use in the USA, and expect it to be a cornerstone of our expanding biologics portfolio,” Pat Miles, NuVasive’s president and chief operating officer, comments.
According to a press release, NuVasive has invested substantially in AttraX putty pre-clinical studies, which it reports have demonstrated improved performance when compared to competitive synthetic bone graft options in challenging posterolateral animal spinal fusion models.
AttraX putty showed increased bone formation and mechanically stronger fusions when compared to Vitoss BA (Stryker) and Actifuse ABX (Baxter) in these studies.
“AttraX Putty has shown promising results in pre-clinical models, highlighted by increased bone formation when compared to traditional osteoconductive synthetic scaffolds. The significant clinical experience with AttraX Putty outside the USA and extensive scientific pre-clinical study is an exciting and promising combination.” says Robert Eastlack, orthopedic surgeon at Scripps Clinic, La Jolla, USA.
